Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer:...

Area of Science:

• Oncology
• Radiation Oncology
• Gynecologic Oncology

Background:

• Locoregionally advanced cervical cancer presents significant treatment challenges.
• Acute toxicities from chemoradiation therapy can impact patient outcomes and quality of life.
• Intensity Modulated Radiation Therapy (IMRT) is a precision radiotherapy technique explored for reducing side effects.

Purpose of the Study:

• To evaluate if Intensity Modulated Radiation Therapy (IMRT) decreases acute hematologic and gastrointestinal (GI) toxicity in patients with advanced cervical cancer.
• To assess the efficacy of positron emission tomography-based image-guided IMRT (IG-IMRT) in reducing neutropenia.
• To analyze patient-reported quality of life changes during treatment.

Main Methods:

• A single-arm, phase II clinical trial conducted across 8 international centers.
• Patients received weekly cisplatin concurrently with daily IMRT, followed by brachytherapy.
• Primary endpoint: incidence of grade ≥3 neutropenia or clinically significant GI toxicity within 30 days post-chemoradiation.

Main Results:

• The overall incidence of primary events (26.5%) was significantly lower than the hypothesized 40% (P=.012).
• Grade ≥3 neutropenia occurred in 19.3% and clinically significant GI toxicity in 12.0% of patients.
• Image-guided IMRT (IG-IMRT) demonstrated a significantly lower incidence of grade ≥3 neutropenia (8.6% vs. 27.1%, P=.035) compared to non-IG-IMRT.

Conclusions:

• IMRT is effective in reducing acute hematologic and GI toxicity for advanced cervical cancer patients.
• IG-IMRT shows a significant benefit in lowering the risk of acute neutropenia.
• These findings suggest IMRT offers a more tolerable and potentially more effective treatment approach.